576 related articles for article (PubMed ID: 15756003)
21. Expression of cancer testis genes in human brain tumors.
Sahin U; Koslowski M; Türeci O; Eberle T; Zwick C; Romeike B; Moringlane JR; Schwechheimer K; Feiden W; Pfreundschuh M
Clin Cancer Res; 2000 Oct; 6(10):3916-22. PubMed ID: 11051238
[TBL] [Abstract][Full Text] [Related]
22. Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma.
Kienstra MA; Neel HB; Strome SE; Roche P
Head Neck; 2003 Jun; 25(6):457-63. PubMed ID: 12784237
[TBL] [Abstract][Full Text] [Related]
23. NY-ESO-1 expression and immunogenicity in esophageal cancer.
Fujita S; Wada H; Jungbluth AA; Sato S; Nakata T; Noguchi Y; Doki Y; Yasui M; Sugita Y; Yasuda T; Yano M; Ono T; Chen YT; Higashiyama M; Gnjatic S; Old LJ; Nakayama E; Monden M
Clin Cancer Res; 2004 Oct; 10(19):6551-8. PubMed ID: 15475443
[TBL] [Abstract][Full Text] [Related]
24. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer.
Akcakanat A; Kanda T; Koyama Y; Watanabe M; Kimura E; Yoshida Y; Komukai S; Nakagawa S; Odani S; Fujii H; Hatakeyama K
Cancer Chemother Pharmacol; 2004 Jul; 54(1):95-100. PubMed ID: 15118836
[TBL] [Abstract][Full Text] [Related]
25. NY-ESO-1 protein expression and humoral immune responses in prostate cancer.
Fosså A; Berner A; Fosså SD; Hernes E; Gaudernack G; Smeland EB
Prostate; 2004 Jun; 59(4):440-7. PubMed ID: 15065093
[TBL] [Abstract][Full Text] [Related]
26. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer.
Sharma P; Gnjatic S; Jungbluth AA; Williamson B; Herr H; Stockert E; Dalbagni G; Donat SM; Reuter VE; Santiago D; Chen YT; Bajorin DF; Old LJ
Cancer Immun; 2003 Dec; 3():19. PubMed ID: 14680360
[TBL] [Abstract][Full Text] [Related]
27. MAGE-A and NY-ESO-1 expression in cervical cancer: prognostic factors and effects of chemotherapy.
Napoletano C; Bellati F; Tarquini E; Tomao F; Taurino F; Spagnoli G; Rughetti A; Muzii L; Nuti M; Benedetti Panici P
Am J Obstet Gynecol; 2008 Jan; 198(1):99.e1-7. PubMed ID: 18166319
[TBL] [Abstract][Full Text] [Related]
28. Infrequent and low expression of cancer-testis antigens located on the X chromosome in colorectal cancer: implications for immunotherapy in South African populations.
Dakshinamurthy AG; Ramesar R; Goldberg P; Blackburn JM
Biotechnol J; 2008 Nov; 3(11):1417-23. PubMed ID: 18956367
[TBL] [Abstract][Full Text] [Related]
29. NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma.
Goydos JS; Patel M; Shih W
J Surg Res; 2001 Jun; 98(2):76-80. PubMed ID: 11397121
[TBL] [Abstract][Full Text] [Related]
30. Expression and significance of cancer testis antigens in primary mucosal melanoma of the head and neck.
Prasad ML; Jungbluth AA; Patel SG; Iversen K; Hoshaw-Woodard S; Busam KJ
Head Neck; 2004 Dec; 26(12):1053-7. PubMed ID: 15515159
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1.
Vaughan HA; Svobodova S; Macgregor D; Sturrock S; Jungbluth AA; Browning J; Davis ID; Parente P; Chen YT; Stockert E; St Clair F; Old LJ; Cebon J
Clin Cancer Res; 2004 Dec; 10(24):8396-404. PubMed ID: 15623618
[TBL] [Abstract][Full Text] [Related]
32. MAGE-A1, GAGE and NY-ESO-1 cancer/testis antigen expression during human gonadal development.
Gjerstorff MF; Kock K; Nielsen O; Ditzel HJ
Hum Reprod; 2007 Apr; 22(4):953-60. PubMed ID: 17208940
[TBL] [Abstract][Full Text] [Related]
33. Potential target antigens for immunotherapy in human pancreatic cancer.
Schmitz-Winnenthal FH; Galindo-Escobedo LV; Rimoldi D; Geng W; Romero P; Koch M; Weitz J; Krempien R; Niethammer AG; Beckhove P; Buchler MW; Z'graggen K
Cancer Lett; 2007 Jul; 252(2):290-8. PubMed ID: 17320278
[TBL] [Abstract][Full Text] [Related]
34. Expression and clinical relevance of NY-ESO-1, MAGE-1 and MAGE-3 in neuroblastoma.
Söling A; Schurr P; Berthold F
Anticancer Res; 1999; 19(3B):2205-9. PubMed ID: 10472332
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic and therapeutic relevance of NY-ESO-1 expression in oral squamous cell carcinoma.
Ries J; Mollaoglu N; Vairaktaris E; Neukam FW; Nkenke E
Anticancer Res; 2009 Dec; 29(12):5125-30. PubMed ID: 20044626
[TBL] [Abstract][Full Text] [Related]
36. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer.
Gure AO; Chua R; Williamson B; Gonen M; Ferrera CA; Gnjatic S; Ritter G; Simpson AJ; Chen YT; Old LJ; Altorki NK
Clin Cancer Res; 2005 Nov; 11(22):8055-62. PubMed ID: 16299236
[TBL] [Abstract][Full Text] [Related]
37. Tumor antigen expression in melanoma varies according to antigen and stage.
Barrow C; Browning J; MacGregor D; Davis ID; Sturrock S; Jungbluth AA; Cebon J
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):764-71. PubMed ID: 16467087
[TBL] [Abstract][Full Text] [Related]
38. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
[TBL] [Abstract][Full Text] [Related]
39. Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease.
Kufer P; Zippelius A; Lutterbüse R; Mecklenburg I; Enzmann T; Montag A; Weckermann D; Passlick B; Prang N; Reichardt P; Dugas M; Köllermann MW; Pantel K; Riethmüller G
Cancer Res; 2002 Jan; 62(1):251-61. PubMed ID: 11782385
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue.
Hudolin T; Juretic A; Spagnoli GC; Pasini J; Bandic D; Heberer M; Kosicek M; Cacic M
Prostate; 2006 Jan; 66(1):13-8. PubMed ID: 16114059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
